CytomX Therapeutics, Inc. Payments to Acquire Debt Securities, Available-for-sale
CytomX Therapeutics, Inc. (CTMX) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2023-03-27
- CytomX Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2022-09-30 was $0.00.
- CytomX Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- CytomX Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- CytomX Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2020-12-31 was $10.10M, a 60.32% decline year-over-year.
- CytomX Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2021 was $99.90M, a 49.83% decline from fiscal 2020.
- CytomX Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2020 was $199.11M, a 13.78% increase from fiscal 2019.
- CytomX Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2019 was $174.99M, a 14.47% decline from fiscal 2018.
- CytomX Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2018 was $204.60M, a 6.45% decline from fiscal 2017.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | |||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $0.00 derived: sum of 2 quarters · filed 2023-03-27 | $99.90M 10-K/A · filed 2023-03-27 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $99.90M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $99.90M 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $10.10M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $154.40M derived: sum of 2 quarters · filed 2023-03-27 | $154.40M derived: sum of 3 quarters · filed 2023-03-27 | $199.11M 10-K/A · filed 2023-03-27 |
| 2020-09-30 | $144.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $144.30M derived: sum of 2 quarters · filed 2020-11-05 | $189.00M 10-Q · filed 2020-11-05 | $214.47M derived: sum of 4 quarters · filed 2023-03-27 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $44.71M 10-Q · filed 2020-08-06 | $70.17M derived: sum of 3 quarters · filed 2023-03-27 | $118.06M derived: sum of 4 quarters · filed 2023-03-27 |
| 2020-03-31 | $44.71M 10-Q · filed 2021-05-06 | $70.17M derived: sum of 2 quarters · filed 2023-03-27 | $118.06M derived: sum of 3 quarters · filed 2023-03-27 | $157.38M derived: sum of 4 quarters · filed 2023-03-27 |
| 2019-12-31 | $25.46M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $73.35M derived: sum of 2 quarters · filed 2023-03-27 | $112.67M derived: sum of 3 quarters · filed 2023-03-27 | $174.99M 10-K/A · filed 2023-03-27 |
| 2019-09-30 | $47.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $87.22M derived: sum of 2 quarters · filed 2020-11-05 | $149.53M 10-Q · filed 2020-11-05 | $192.39M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $39.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $101.64M 10-Q · filed 2020-08-06 | $144.50M derived: sum of 3 quarters · filed 2021-02-24 | $206.61M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $62.32M 10-Q · filed 2020-05-07 | $105.17M derived: sum of 2 quarters · filed 2021-02-24 | $167.29M derived: sum of 3 quarters · filed 2021-02-24 | $218.79M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $42.86M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $104.97M derived: sum of 2 quarters · filed 2021-02-24 | $156.47M derived: sum of 3 quarters · filed 2021-02-24 | $204.60M 10-K · filed 2021-02-24 |
| 2018-09-30 | $62.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $113.61M derived: sum of 2 quarters · filed 2019-11-07 | $161.74M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $51.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $99.63M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $48.13M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $218.71M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $121.52M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |